Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltanexor in Relapsed/Refractory NPM1-Mutated AML
2024-514724-16-01Phase 2Authorised
- Sponsor
- Azienda Ospedaliero-Universitaria delle Marche
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltanexor in acute myeloid leukemia (AML), sponsored by Azienda Ospedaliero-Universitaria delle Marche. Primary endpoints: Response rate by end of cycle 2 and Rate of severe adverse events. Planned start Jan 2025; status: authorised.
02
Drugs
eltanexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-514724-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514724-16-01.